Indivumed Therapeutics
Dr. rer. nat. Frauke Degenhardt is a Data Scientist at Indivumed Group since August 2022, specializing in therapeutic target discovery and multi-OMICs analysis in cancer through classical statistical and machine learning techniques. Previously, Dr. Degenhardt served as a Postdoctoral Researcher at the Institute of Clinical Molecular Biology from August 2013 to August 2022, focusing on statistical analysis of COVID-19 genetics and HLA genetics across various disease contexts, while coordinating projects within the Severe COVID-19 GWAS consortium. Dr. Degenhardt also has experience as a Doctoral Student, emphasizing clinical and multi-OMICs data analysis, and has engaged in pipeline design for HLA imputation. Academic qualifications include a Doctor of Science in Computational Biology from Kiel University, a Master's degree in Computational Life Science from Universität zu Lübeck, and a Bachelor's degree in Molecular Life Science from the same institution.
Indivumed Therapeutics
1 followers
Twenty years of innovation, but a vision that remains unchanged. Valued for the standardized collection and analysis of tissue samples that has enabled a truly unique multi-omics database, we are on the verge of reshaping what is possible in the field of precision oncology. We have unlocked an understanding of the molecular reality of cancer at an unparalleled level that is now supporting biomarker and target discovery and validation, drug development, and clinical trial performance. We continue striving for a world where precision therapy is possible for each individual cancer patient. To learn more about our mission, visit www.indivumed-therapeutics.com.